verapamil has been researched along with Chronic Disease in 147 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 9.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
"Racemic (R /S)- verapamil is widely used in the management of chronic atrial fibrillation." | 9.09 | Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ( Busse, D; Drescher, S; Eichelbaum, M; Fromm, MF; Kühlkamp, V; Mörike, K, 2001) |
"In a placebo-controlled study the effects on ventricular rate regulation and exercise performance of xamoterol, 100 mg two times a day and 200 mg two times a day, and slow-release verapamil, 240 mg once a day, were assessed in 21 patients with chronic atrial fibrillation." | 9.07 | Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. ( Lundström, T; Moor, E; Rydén, L, 1992) |
"The results of an open clinical trial carried out between 1985 and 1989, studying the effect of calcium antagonists, particularly verapamil, on chronic diarrhea of different etiologies, are presented." | 9.07 | [The therapeutic effects of the calcium blocker verapamil in chronic diarrhea. Preliminary communication]. ( Borsari, G, 1991) |
"Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination." | 9.06 | Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. ( Irvine, N; Lewis, RV; McDevitt, DG, 1988) |
"The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris." | 9.06 | Efficacy of sustained-release verapamil in chronic stable angina pectoris. ( Cutler, SS; Klein, MD; Weiner, DA, 1987) |
" The efficacy of verapamil alone, or in combination with digoxin, was compared with digoxin alone in eight patients with chronic atrial fibrillation in this double-blind placebo-controlled study." | 9.06 | Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. ( Beasley, CR; Challenor, V; Holgate, ST; Pomfret, SM, 1988) |
"The comparative effects of prolonged chronic therapy with diltiazem, nicardipine, tiapamil and verapamil on exercise tolerance, ST-segment changes and heart rate were examined in 63 patients with established chronic stable angina pectoris." | 9.06 | Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris. ( Khurmi, NS; Raftery, EB, 1987) |
"The efficacy and effect on cardiac function of verapamil 120 mg three times a day and atenolol 100 mg once a day, singly and in combination, were evaluated in 15 patients with angina pectoris." | 9.06 | A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. ( Aitchison, T; Dargie, HJ; Elliott, AT; Findlay, IN; Gillen, G; MacLeod, K, 1987) |
"Twelve patients (including 2 females) with chronic atrial fibrillation were entered into a randomized, double blind crossover study to compare the effects of digoxin and verapamil upon heart rate, exercise tolerance and symptom control." | 9.06 | A comparison of verapamil and digoxin in the treatment of atrial fibrillation. ( Lakhani, M; Lewis, R; McDevitt, DG; Moreland, TA, 1987) |
"The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study." | 9.05 | Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. ( Baessler, C; Morganroth, J; Panidis, IP, 1983) |
"The comparative effects of diltiazem and verapamil in 30 patients with long-standing atrial fibrillation were evaluated in a prospective clinical trial." | 9.05 | Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation. ( Anda, L; Eichelbaum, M; Greenblatt, DJ; Ochs, HR, 1985) |
"We evaluated the effectiveness of oral verapamil therapy for control of ventricular rate in digitalized patients with atrial fibrillation (AF) with three clinical problems: chronic AF with rapid rate at rest (four patients), chronic AF with accelerated rate during modest exercise (five patients), and rapid rates during paroxysmal AF (four patients)." | 9.05 | Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. ( Guerrero, J; King, BD; Pitchon, R; Schneider, RR; Stern, EH; Wiener, I, 1982) |
"The objective was to assess the effect ofverapamil on atrial fibrillation (AF) cycle length and spatial dispersion of refractoriness in patients with chronic AF." | 7.71 | Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. ( de Bakker, JM; Elvan, A; Hauer, RN; Ramanna, H; Robles de Medina, EO; Wittkampf, FH, 2001) |
"The effect of verapamil on long-term tachycardia-induced atrial electrical remodeling has not been reported." | 7.70 | Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. ( Chang, MS; Chen, SA; Cheng, JJ; Ding, YA; Hung, CR; Lee, SH; Yu, WC, 2000) |
" Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 7.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
"Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil." | 7.70 | Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. ( Carlson, J; Ingemansson, MP; Lindholm, CJ; Meurling, CJ; Olsson, SB; Roijer, A; Smideberg, B; Sornmo, L; Stridh, M, 1999) |
"Patients with chronic isolated atrial fibrillation underwent maximal exercise testing before and after the administration of digoxin, propranolol, or verapamil." | 7.68 | Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. ( Haraguchi, M; Kusukawa, R; Matsuda, M; Matsuda, Y; Tada, T; Takahashi, T; Yamagishi, T, 1991) |
"Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 7.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
"This study was designed to examine the mechanisms that contribute to the chronic hypotensive effects of verapamil during angiotensin II-induced hypertension." | 7.67 | Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent. ( Lohmeier, TE; Montani, JP; Rushing, EL; Smith, MJ, 1989) |
"This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 6.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
" This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 6.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
"Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 6.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
"Verapamil and digoxin have been shown to modulate tachycardia-induced atrial electrical remodeling." | 5.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
"In previous work, we have shown that the chronic administration of verapamil, a calcium channel blocker, ameliorated the mortality, pathology, and biochemical alterations associated with acute murine Chagas' disease." | 5.28 | Effect of verapamil on the development of chronic experimental Chagas' disease. ( Bilezikian, JP; Factor, SM; Morris, SA; Tanowitz, HB; Weiss, LM; Wittner, M, 1989) |
" Trough serum concentration of verapamil did not differ during the two dosage regimens (59 ng/ml - conventional formulation and 49." | 5.27 | 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. ( Bjerregaard, P; Jørgensen, HS; Klitgaard, NA; Mølgaard, H, 1987) |
"Verapamil, 0." | 5.27 | Efficacy of verapamil in chronic, recurrent ventricular tachycardia. ( Mason, JW; Mitchell, LB; Swerdlow, CD, 1983) |
"Treatment with Verapamil or aspirin reduced both chronic hypoxic pulmonary hypertension and the hypertrophy of the right ventricle." | 5.26 | Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Kentera, D; Susić, D; Zdravković, M, 1979) |
"Verapamil disposition was studied in 12 patients with chronic and fibrillation." | 5.26 | Verapamil disposition kinetics in chronic atrial fibrillation. ( Harapat, S; Harrison, DC; Kates, RE; Keefe, DL; Kirsten, EB; Schwartz, J, 1981) |
"To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 5.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
"The prognostic significance of ambulatory ischemia, alone and in relation to ischemia during exercise was assessed in 686 patients (475 men) with chronic stable angina pectoris taking part in the Angina Prognosis Study In Stockholm (APSIS), who had 24-hour ambulatory electrocardiographic registrations and exercise tests at baseline (n = 678) and after 1 month (n = 607) of double-blind treatment with metoprolol or verapamil." | 5.09 | Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1999) |
"There were no significant differences in preoperative mean intraocular pressure, mean number of medications, and glaucoma severity between the verapamil and placebo groups." | 5.09 | Topical verapamil in glaucoma filtration surgery. ( Hughes, BA; Juzych, MS; Kardasis, CT; Keole, NS; Kim, C; Shin, DH, 2001) |
"Racemic (R /S)- verapamil is widely used in the management of chronic atrial fibrillation." | 5.09 | Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ( Busse, D; Drescher, S; Eichelbaum, M; Fromm, MF; Kühlkamp, V; Mörike, K, 2001) |
"We studied the effects of the mode of cardioversion on Doppler left atrial and appendage function in 19 patients with persistent atrial fibrillation (> or = 4 weeks), who were randomized to pharmacological (quinidine) or electrical cardioversion (protocol: 200, 300, 360 J) after pre-treatment with verapamil." | 5.09 | Left atrial and appendage mechanical function after pharmacological or electrical cardioversion in patients with chronic atrial fibrillation: a multicenter, randomized study. ( Cattarini, G; Mazzone, C; Miccio, M; Morgera, T; Pandullo, C; Salvi, R; Scardi, S, 2000) |
"In a placebo-controlled study the effects on ventricular rate regulation and exercise performance of xamoterol, 100 mg two times a day and 200 mg two times a day, and slow-release verapamil, 240 mg once a day, were assessed in 21 patients with chronic atrial fibrillation." | 5.07 | Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. ( Lundström, T; Moor, E; Rydén, L, 1992) |
"The results of an open clinical trial carried out between 1985 and 1989, studying the effect of calcium antagonists, particularly verapamil, on chronic diarrhea of different etiologies, are presented." | 5.07 | [The therapeutic effects of the calcium blocker verapamil in chronic diarrhea. Preliminary communication]. ( Borsari, G, 1991) |
" The efficacy of verapamil alone, or in combination with digoxin, was compared with digoxin alone in eight patients with chronic atrial fibrillation in this double-blind placebo-controlled study." | 5.06 | Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. ( Beasley, CR; Challenor, V; Holgate, ST; Pomfret, SM, 1988) |
"Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination." | 5.06 | Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. ( Irvine, N; Lewis, RV; McDevitt, DG, 1988) |
"The comparative effects of prolonged chronic therapy with diltiazem, nicardipine, tiapamil and verapamil on exercise tolerance, ST-segment changes and heart rate were examined in 63 patients with established chronic stable angina pectoris." | 5.06 | Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris. ( Khurmi, NS; Raftery, EB, 1987) |
"Twelve patients (including 2 females) with chronic atrial fibrillation were entered into a randomized, double blind crossover study to compare the effects of digoxin and verapamil upon heart rate, exercise tolerance and symptom control." | 5.06 | A comparison of verapamil and digoxin in the treatment of atrial fibrillation. ( Lakhani, M; Lewis, R; McDevitt, DG; Moreland, TA, 1987) |
"The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris." | 5.06 | Efficacy of sustained-release verapamil in chronic stable angina pectoris. ( Cutler, SS; Klein, MD; Weiner, DA, 1987) |
"The efficacy and effect on cardiac function of verapamil 120 mg three times a day and atenolol 100 mg once a day, singly and in combination, were evaluated in 15 patients with angina pectoris." | 5.06 | A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. ( Aitchison, T; Dargie, HJ; Elliott, AT; Findlay, IN; Gillen, G; MacLeod, K, 1987) |
"Patients with atrial fibrillation frequently show a wide variation in heart rate with digoxin therapy." | 5.06 | Towards improved control of atrial fibrillation. ( Channer, KS; James, MA; Papouchado, M; Pitcher, DW; Rees, JR, 1987) |
"The efficacy of verapamil (360 mg daily) in the treatment of patients with chronic stable angina pectoris was compared with placebo." | 5.05 | Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. ( Lahiri, A; Paramasivan, R; Raftery, EB; Subramanian, VB, 1980) |
"We evaluated the effectiveness of oral verapamil therapy for control of ventricular rate in digitalized patients with atrial fibrillation (AF) with three clinical problems: chronic AF with rapid rate at rest (four patients), chronic AF with accelerated rate during modest exercise (five patients), and rapid rates during paroxysmal AF (four patients)." | 5.05 | Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. ( Guerrero, J; King, BD; Pitchon, R; Schneider, RR; Stern, EH; Wiener, I, 1982) |
"The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study." | 5.05 | Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. ( Baessler, C; Morganroth, J; Panidis, IP, 1983) |
"Propranolol (240 mg daily) and verapamil (360 mg daily) were objectively compared for their respective efficacy in the treatment of chronic stable angina pectoris." | 5.05 | Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina. ( Bala Subramanian, V; Bowles, MJ; Davies, AB; Raftery, EB, 1983) |
"The comparative effects of diltiazem and verapamil in 30 patients with long-standing atrial fibrillation were evaluated in a prospective clinical trial." | 5.05 | Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation. ( Anda, L; Eichelbaum, M; Greenblatt, DJ; Ochs, HR, 1985) |
"The regeneratory reactions of cardiomyocytes in the heart under conditions of cytopathic exposure to hypercholesterolemia and during verapamil treatment were studied by immunohistochemical detection of proliferation marker Ki-67 and evaluation of cardiomyocyte count." | 3.81 | Stimulation of Cardiomyocyte Regeneratory Reactions under Conditions of Cytopathic Hypercholesterolemia. ( Klinnikova, MG; Lushnikova, EL; Nepomnyashchikh, LM; Yuzhik, EI, 2015) |
"The objective was to assess the effect ofverapamil on atrial fibrillation (AF) cycle length and spatial dispersion of refractoriness in patients with chronic AF." | 3.71 | Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. ( de Bakker, JM; Elvan, A; Hauer, RN; Ramanna, H; Robles de Medina, EO; Wittkampf, FH, 2001) |
" Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 3.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
"The effect of verapamil on long-term tachycardia-induced atrial electrical remodeling has not been reported." | 3.70 | Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. ( Chang, MS; Chen, SA; Cheng, JJ; Ding, YA; Hung, CR; Lee, SH; Yu, WC, 2000) |
"Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil." | 3.70 | Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. ( Carlson, J; Ingemansson, MP; Lindholm, CJ; Meurling, CJ; Olsson, SB; Roijer, A; Smideberg, B; Sornmo, L; Stridh, M, 1999) |
"Vasospasm has been implicated as a cause of amaurosis fugax, which can be controlled by administration of the calcium channel blockers nifedipine or verapamil." | 3.69 | Recovery from ocular ischemic syndrome after treatment with verapamil. ( Beckman, RL; Winterkorn, JM, 1995) |
"Patients with chronic isolated atrial fibrillation underwent maximal exercise testing before and after the administration of digoxin, propranolol, or verapamil." | 3.68 | Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. ( Haraguchi, M; Kusukawa, R; Matsuda, M; Matsuda, Y; Tada, T; Takahashi, T; Yamagishi, T, 1991) |
"This study was designed to examine the mechanisms that contribute to the chronic hypotensive effects of verapamil during angiotensin II-induced hypertension." | 3.67 | Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent. ( Lohmeier, TE; Montani, JP; Rushing, EL; Smith, MJ, 1989) |
"Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 3.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
"Catheterization of the pulmonary artery and radiocirculography were used in 30 patients with chronic bronchitis (CB) in order to study changes in hemodynamics induced by intravenous injections of 5 and 10 mg verapamil or by 4-5 weeks of the treatment with finoptin and corinfar." | 3.67 | [The effect of calcium antagonists on pulmonary hemodynamics in patients with chronic bronchitis with manifest and latent pulmonary hypertension]. ( Volkova, LI, 1989) |
"The effect of verapamil on the pharmacokinetics of digoxin was studied in 49 patients with chronic atrial fibrillation." | 3.66 | The influence of verapamil on serum digoxin concentration. ( Di Segni, E; Guerrero, J; Kaplinsky, E; Klein, HO; Lang, R; Libhaber, C; Weiss, E, 1982) |
"This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 2.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
" This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 2.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
"The efficacy of verapamil CR in migraine prophylaxis has been tested in an open study with 64 patients." | 2.67 | [The use of verapamil in the treatment of hemicrania without aura]. ( Farinini, D; Fonzari, M; Santoloci, D, 1994) |
"Chronic Cluster Headache (CCH) treatment is troublesome; since there are no pain-free periods, it must be continuous." | 2.67 | Double blind comparison of lithium and verapamil in cluster headache prophylaxis. ( Bussone, G; Granella, F; Leone, M; Magri, M; Manzoni, GC; Micieli, G; Nappi, G; Peccarisi, C, 1990) |
"Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0." | 2.66 | Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. ( Lewis, RV; McDevitt, DG; McMurray, J, 1989) |
" In this dosage nifedipine did not show any significant change in exercise duration and the variables obtained using computer assisted exercise testing when compared to placebo." | 2.65 | Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. ( Bowles, MJ; Davies, AB; Khurmi, NS; Raftery, EB; Subramanian, VB, 1984) |
"Verapamil is proving to be an important addition to existing drug regimens available for the treatment of stable angina pectoris." | 2.65 | Verapamil in treatment of chronic stable angina. ( Charlap, S; Frishman, WH, 1983) |
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
"Headaches are a common entity in the ambulatory population." | 2.40 | Diagnosis, prophylaxis, and treatment of headaches in the athlete. ( Kaplan, B; Swain, RA, 1997) |
"Ventricular tachycardia was suppressed by administration of Lidocaine." | 2.39 | [The efficacy of verapamil in sustained monomorphic ventricular tachycardia]. ( Barrenetxea, JI; Bodegas, A; Montes, PM; Rodrigo, D; Rumoroso, JR; Sanz, R; Subinas, J, 1994) |
"Verapamil was specifically found to reduce airway goblet cell hyperplasia and eosinophilic infiltration in a murine asthma model." | 1.42 | Verapamil modulates interleukin-5 and interleukin-6 secretion in organotypic human sinonasal polyp explants. ( Bleier, BS; Han, X; Kocharyan, A; Singleton, A, 2015) |
"At least, part of antiseizure effects of cannabinoid compounds is mediated through calcium (Ca(2+)) channels." | 1.38 | L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure. ( Ahmad-Molaei, L; Eslahkar, S; Mazar-Atabaki, A; Motiei-Langroudi, SM; Naderi, N; Ronaghi, A; Shirazi-zand, Z, 2012) |
"It is useful for refractory cluster headache, is more effective for the episodic form than the chronic form, and has a rapid onset of action." | 1.32 | Outpatient intravenous dihydroergotamine for refractory cluster headache. ( Magnoux, E; Zlotnik, G, 2004) |
"In episodic cluster headache early treatment onset stopped attacks within 20 days in 80%, late treatment onset was successful within ten days in 67%." | 1.32 | [Prophylactic treatment of cluster headache with verapamil]. ( Stallmach, M, 2003) |
"Verapamil and digoxin have been shown to modulate tachycardia-induced atrial electrical remodeling." | 1.31 | Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation. ( Allessie, MA; Duytschaever, MF; Garratt, CJ, 2000) |
"Chronic cluster headache was diagnosed, and he was given verapamil, 360 mg per day." | 1.31 | Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report. ( Albano, O; Bassi, A; Causarano, V; Centonze, A; Centonze, V; Dalfino, L, 2000) |
"We report a case of an almost permanent ventricular tachycardia that occurred in a 39-year-old man a few weeks before admission to the hospital." | 1.29 | Chronic irregular idiopathic ventricular tachycardia with myocardial dysfunction suppressed by verapamil in an adult. ( Cachin, JC; Castaigne, A; Lellouche, D; Nghiem, DK; Perez, Y, 1994) |
"After two days of complete remission, cluster headache attacks reappeared and persisted until verapamil, 360 mg a day, was added to indomethacin." | 1.28 | Ipsilateral cluster headache and chronic paroxysmal hemicrania: two case reports. ( Bousser, MG; Tehindrazanarivelo, AD; Visy, JM, 1992) |
"Verapamil was found to diminish depression of neutrophil chemiluminescence both at rest and following activation with opsonized zymosan." | 1.28 | Effect of verapamil on chemiluminescence of peripheral blood neutrophils during hemodialysis in chronic uremic patients. ( Kantorski, J; Luciak, M; Pawlicki, L; Pokoca, L; Tchórzewski, H; Trznadel, K, 1989) |
"In previous work, we have shown that the chronic administration of verapamil, a calcium channel blocker, ameliorated the mortality, pathology, and biochemical alterations associated with acute murine Chagas' disease." | 1.28 | Effect of verapamil on the development of chronic experimental Chagas' disease. ( Bilezikian, JP; Factor, SM; Morris, SA; Tanowitz, HB; Weiss, LM; Wittner, M, 1989) |
" Trough serum concentration of verapamil did not differ during the two dosage regimens (59 ng/ml - conventional formulation and 49." | 1.27 | 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. ( Bjerregaard, P; Jørgensen, HS; Klitgaard, NA; Mølgaard, H, 1987) |
"Verapamil, 0." | 1.27 | Efficacy of verapamil in chronic, recurrent ventricular tachycardia. ( Mason, JW; Mitchell, LB; Swerdlow, CD, 1983) |
"Verapamil disposition was studied in 12 patients with chronic and fibrillation." | 1.26 | Verapamil disposition kinetics in chronic atrial fibrillation. ( Harapat, S; Harrison, DC; Kates, RE; Keefe, DL; Kirsten, EB; Schwartz, J, 1981) |
"Treatment with Verapamil or aspirin reduced both chronic hypoxic pulmonary hypertension and the hypertrophy of the right ventricle." | 1.26 | Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Kentera, D; Susić, D; Zdravković, M, 1979) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 80 (54.42) | 18.7374 |
1990's | 36 (24.49) | 18.2507 |
2000's | 21 (14.29) | 29.6817 |
2010's | 8 (5.44) | 24.3611 |
2020's | 2 (1.36) | 2.80 |
Authors | Studies |
---|---|
Workman, AD | 1 |
Mueller, SK | 1 |
McDonnell, K | 1 |
Goldfarb, JW | 1 |
Bleier, BS | 4 |
Bobenko, AI | 1 |
Heller, S | 1 |
Schmitt, N | 1 |
Cherdtrakulkiat, R | 1 |
Lawung, R | 1 |
Nabu, S | 1 |
Tantimavanich, S | 1 |
Sinthupoom, N | 1 |
Prachayasittikul, S | 1 |
Prachayasittikul, V | 1 |
Zhang, B | 1 |
Wu, C | 1 |
Zhang, Z | 2 |
Yan, K | 1 |
Li, C | 2 |
Li, Y | 4 |
Li, L | 3 |
Zheng, C | 1 |
Xiao, Y | 1 |
He, D | 1 |
Zhao, F | 1 |
Su, JF | 1 |
Lun, SM | 1 |
Hou, YJ | 1 |
Duan, LJ | 1 |
Wang, NC | 1 |
Shen, FF | 1 |
Zhang, YW | 1 |
Gao, ZW | 1 |
Li, J | 5 |
Du, XJ | 1 |
Zhou, FY | 1 |
Yin, Z | 1 |
Zhu, J | 2 |
Yan, D | 1 |
Lou, H | 1 |
Yu, H | 1 |
Feng, C | 1 |
Wang, Z | 1 |
Wang, Y | 4 |
Hu, X | 1 |
Li, Z | 2 |
Shen, Y | 1 |
Hu, D | 1 |
Chen, H | 1 |
Wu, X | 1 |
Duan, Y | 1 |
Zhi, D | 1 |
Zou, M | 2 |
Zhao, Z | 1 |
Zhang, X | 2 |
Yang, X | 2 |
Zhang, J | 2 |
Wang, H | 1 |
Popović, KJ | 1 |
Popović, DJ | 1 |
Miljković, D | 1 |
Lalošević, D | 1 |
Čapo, I | 1 |
Popović, JK | 1 |
Liu, M | 1 |
Song, H | 2 |
Xing, Z | 1 |
Lu, G | 1 |
Chen, D | 1 |
Valentini, AM | 1 |
Di Pinto, F | 1 |
Coletta, S | 1 |
Guerra, V | 1 |
Armentano, R | 1 |
Caruso, ML | 1 |
Gong, J | 1 |
Wang, N | 1 |
Bian, L | 1 |
Wang, M | 1 |
Ye, M | 1 |
Wen, N | 1 |
Fu, M | 1 |
Fan, W | 1 |
Meng, Y | 1 |
Dong, G | 1 |
Lin, XH | 1 |
Liu, HH | 1 |
Gao, DM | 1 |
Cui, JF | 1 |
Ren, ZG | 1 |
Chen, RX | 1 |
Önal, B | 1 |
Özen, D | 1 |
Demir, B | 1 |
Akkan, AG | 1 |
Özyazgan, S | 1 |
Payette, G | 1 |
Geoffroy, V | 1 |
Martineau, C | 1 |
Villemur, R | 1 |
Jameel, T | 1 |
Baig, M | 1 |
Gazzaz, ZJ | 1 |
Tashkandi, JM | 1 |
Al Alhareth, NS | 1 |
Khan, SA | 1 |
Butt, NS | 1 |
Wang, J | 2 |
Geng, Y | 1 |
Zhang, Y | 3 |
Wang, X | 2 |
Liu, J | 2 |
Basit, A | 1 |
Miao, T | 1 |
Liu, W | 1 |
Jiang, W | 1 |
Yu, ZY | 1 |
Wu, L | 2 |
Qu, B | 1 |
Sun, JX | 1 |
Cai, AL | 1 |
Xie, LM | 1 |
Groeneveld, J | 1 |
Ho, SL | 1 |
Mackensen, A | 1 |
Mohtadi, M | 1 |
Laepple, T | 1 |
Genovesi, S | 1 |
Nava, E | 1 |
Bartolucci, C | 1 |
Severi, S | 1 |
Vincenti, A | 1 |
Contaldo, G | 1 |
Bigatti, G | 1 |
Ciurlino, D | 1 |
Bertoli, SV | 1 |
Slovak, JE | 1 |
Hwang, JK | 1 |
Rivera, SM | 1 |
Villarino, NF | 1 |
Li, S | 1 |
Cao, G | 1 |
Ling, M | 1 |
Ji, J | 1 |
Zhao, D | 1 |
Sha, Y | 1 |
Gao, X | 1 |
Liang, C | 2 |
Guo, Q | 1 |
Zhou, C | 1 |
Ma, Z | 1 |
Xu, J | 1 |
Wang, C | 1 |
Zhao, W | 1 |
Xia, X | 1 |
Jiang, Y | 1 |
Peng, J | 1 |
Jia, Z | 1 |
Li, F | 1 |
Chen, X | 2 |
Mo, J | 1 |
Zhang, S | 2 |
Li, X | 1 |
Huang, T | 1 |
Zhu, Q | 1 |
Wang, S | 1 |
Ge, RS | 1 |
Fortunato, G | 1 |
Lin, J | 2 |
Agarwal, PK | 1 |
Kohen, A | 1 |
Singh, P | 1 |
Cheatum, CM | 1 |
Zhu, D | 1 |
Hayman, A | 1 |
Kebede, B | 1 |
Stewart, I | 1 |
Chen, G | 1 |
Frew, R | 1 |
Guo, X | 1 |
Gong, Q | 1 |
Borowiec, J | 1 |
Han, S | 1 |
Zhang, M | 1 |
Willis, M | 1 |
Kreouzis, T | 1 |
Yu, K | 1 |
Chirvony, VS | 1 |
Sekerbayev, KS | 1 |
Pérez-Del-Rey, D | 1 |
Martínez-Pastor, JP | 1 |
Palazon, F | 1 |
Boix, PP | 1 |
Taurbayev, TI | 1 |
Sessolo, M | 1 |
Bolink, HJ | 1 |
Lu, M | 1 |
Lan, Y | 1 |
Xiao, J | 1 |
Song, M | 1 |
Chen, C | 1 |
Huang, Q | 1 |
Cao, Y | 1 |
Ho, CT | 1 |
Qi, B | 1 |
Wang, Q | 1 |
Zhang, W | 1 |
Fang, L | 1 |
Xie, CL | 1 |
Chen, R | 1 |
Yang, S | 1 |
Xia, JM | 1 |
Zhang, GY | 1 |
Chen, CH | 1 |
Yang, XW | 1 |
Domenech-Ximenos, B | 1 |
Garza, MS | 1 |
Prat-González, S | 1 |
Sepúlveda-Martínez, Á | 1 |
Crispi, F | 1 |
Perea, RJ | 1 |
Garcia-Alvarez, A | 1 |
Sitges, M | 1 |
Kalumpha, M | 1 |
Guyo, U | 1 |
Zinyama, NP | 1 |
Vakira, FM | 1 |
Nyamunda, BC | 1 |
Varga, M | 1 |
Drácz, L | 1 |
Kolbenheyer, E | 1 |
Varga, F | 1 |
Patai, ÁV | 1 |
Solymosi, N | 1 |
Patai, Á | 1 |
Kiss, J | 1 |
Gaál, V | 1 |
Nyul, Z | 1 |
Mosdósi, B | 1 |
Valdez, M | 1 |
Moosavi, L | 1 |
Heidari, A | 1 |
Novakovic-Agopian, T | 1 |
Kornblith, E | 1 |
Abrams, G | 1 |
McQuaid, JR | 1 |
Posecion, L | 1 |
Burciaga, J | 1 |
D'Esposito, M | 1 |
Chen, AJW | 1 |
Samy El Gendy, NM | 1 |
Wesolowska, P | 1 |
Georg, D | 1 |
Lechner, W | 1 |
Kazantsev, P | 1 |
Bokulic, T | 1 |
Tedgren, AC | 1 |
Adolfsson, E | 1 |
Campos, AM | 1 |
Alves, VGL | 1 |
Suming, L | 1 |
Hao, W | 1 |
Ekendahl, D | 1 |
Koniarova, I | 1 |
Bulski, W | 1 |
Chelminski, K | 1 |
Samper, JLA | 1 |
Vinatha, SP | 1 |
Rakshit, S | 1 |
Siri, S | 1 |
Tomsejm, M | 1 |
Tenhunen, M | 1 |
Povall, J | 1 |
Kry, SF | 1 |
Followill, DS | 1 |
Thwaites, DI | 1 |
Izewska, J | 1 |
Kang, JH | 1 |
Yoon, Y | 1 |
Song, J | 1 |
Van de Winckel, A | 1 |
Gauthier, L | 1 |
Chao, CT | 1 |
Lee, YH | 1 |
Li, CM | 1 |
Han, DS | 1 |
Huang, JW | 1 |
Huang, KC | 1 |
Ni, L | 1 |
Güttinger, R | 1 |
Triana, CA | 1 |
Spingler, B | 1 |
Baldridge, KK | 1 |
Patzke, GR | 1 |
Shen, X | 1 |
Wang, B | 1 |
Xie, S | 1 |
Deng, W | 1 |
Wu, D | 1 |
Zhang, Q | 1 |
Voskamp, BJ | 1 |
Peelen, MJCS | 1 |
Ravelli, ACJ | 1 |
van der Lee, R | 1 |
Mol, BWJ | 1 |
Pajkrt, E | 1 |
Ganzevoort, W | 1 |
Kazemier, BM | 1 |
Tibrewala, R | 1 |
Bahroos, E | 1 |
Mehrabian, H | 1 |
Foreman, SC | 1 |
Link, TM | 1 |
Pedoia, V | 1 |
Majumdar, S | 1 |
Jablonski, CL | 1 |
Leonard, C | 1 |
Salo, P | 1 |
Krawetz, RJ | 1 |
Yoon, N | 1 |
Hong, SN | 1 |
Cho, JG | 1 |
Jeong, HK | 1 |
Lee, KH | 1 |
Park, HW | 1 |
Barman, S | 1 |
Konai, MM | 1 |
Samaddar, S | 1 |
Haldar, J | 1 |
Mohamed, HSH | 1 |
Li, CF | 1 |
Hu, ZY | 1 |
Deng, Z | 1 |
Chen, LH | 1 |
Su, BL | 1 |
Chu, K | 1 |
Liu, YP | 1 |
Li, YB | 1 |
Zhang, H | 1 |
Xu, C | 1 |
Zou, Z | 1 |
Wu, Z | 1 |
Xia, Y | 1 |
Zhao, P | 1 |
Wang, HT | 1 |
de Biase, S | 1 |
Pellitteri, G | 1 |
Gigli, GL | 1 |
Valente, M | 1 |
van Weperen, VYH | 1 |
Bossu, A | 1 |
Vos, MA | 1 |
Taha, MS | 1 |
Nocera, A | 2 |
Workman, A | 1 |
Amiji, MM | 1 |
Speerschneider, T | 1 |
Thomsen, MB | 1 |
Kocharyan, A | 1 |
Singleton, A | 1 |
Han, X | 1 |
Lushnikova, EL | 1 |
Yuzhik, EI | 1 |
Klinnikova, MG | 1 |
Nepomnyashchikh, LM | 1 |
Miyake, MM | 1 |
Levesque, P | 1 |
Guo, R | 1 |
Finn, CA | 1 |
Goldfarb, J | 1 |
Gray, S | 1 |
Holbrook, E | 1 |
Busaba, N | 1 |
Dolci, JEL | 1 |
Björkander, I | 3 |
Forslund, L | 3 |
Ericson, M | 1 |
Rehnqvist, N | 3 |
Hjemdahl, P | 3 |
Kahan, T | 1 |
Naderi, N | 1 |
Ahmad-Molaei, L | 1 |
Mazar-Atabaki, A | 1 |
Ronaghi, A | 1 |
Shirazi-zand, Z | 1 |
Motiei-Langroudi, SM | 1 |
Eslahkar, S | 1 |
Paulis, G | 1 |
Cavallini, G | 1 |
Brancato, T | 1 |
Alvaro, R | 1 |
Gavrish, AS | 1 |
Verbitskiĭ, VV | 1 |
Shchul'ts, NV | 1 |
Danilishina, MV | 1 |
Scherer, M | 1 |
Dzemali, O | 1 |
Aybek, T | 1 |
Wimmer-Greinecker, G | 1 |
Moritz, A | 1 |
Stallmach, M | 1 |
Magnoux, E | 1 |
Zlotnik, G | 1 |
Afridi, S | 1 |
Bacon, CM | 1 |
Bowling, J | 1 |
Goadsby, PJ | 1 |
Ducros, A | 1 |
Subramanian, VB | 3 |
Lahiri, A | 2 |
Paramasivan, R | 1 |
Raftery, EB | 5 |
Lewis, GR | 1 |
Frishman, WH | 5 |
Charlap, S | 4 |
Bowles, MJ | 3 |
Bala Subramanian, V | 2 |
Davies, AB | 3 |
Panidis, IP | 1 |
Morganroth, J | 1 |
Baessler, C | 1 |
Katsenovich, RA | 1 |
Kostko, SZ | 1 |
Arifdzhanova, UA | 1 |
Khashimov, KhA | 1 |
Vakhidova, MA | 1 |
Lessem, J | 1 |
Khurmi, NS | 3 |
Candau, LA | 2 |
Pereira, LS | 1 |
Lavall, MA | 1 |
Carvalho, CR | 1 |
Shinbaeva, NA | 1 |
Vygodin, VA | 1 |
Martsevich, SIu | 1 |
Metelitsa, VI | 2 |
Mason, JW | 1 |
Swerdlow, CD | 1 |
Mitchell, LB | 1 |
Albanese, C | 1 |
Di Mario, F | 1 |
Dawson, JR | 1 |
Whitaker, NH | 1 |
Sutton, GC | 1 |
Stern, EH | 1 |
Pitchon, R | 1 |
King, BD | 1 |
Guerrero, J | 2 |
Schneider, RR | 1 |
Wiener, I | 1 |
Klein, HO | 2 |
Lang, R | 1 |
Weiss, E | 1 |
Di Segni, E | 2 |
Libhaber, C | 1 |
Kaplinsky, E | 2 |
Schwartz, JB | 1 |
Keefe, D | 1 |
Kates, RE | 2 |
Kirsten, E | 1 |
Harrison, DC | 2 |
Kuan, P | 1 |
Reuben, SR | 1 |
Gale, EV | 1 |
Wilde, PM | 1 |
Widimský, J | 1 |
Jandová, R | 1 |
Frídl, P | 1 |
Ostádal, B | 1 |
Keefe, DL | 2 |
Schwartz, J | 1 |
Harapat, S | 1 |
Kirsten, EB | 1 |
Rosengarten, MD | 1 |
Leclercq, JF | 1 |
Coumel, PH | 1 |
Rabkin, SW | 1 |
Tomlinson, C | 1 |
Corbett, BN | 1 |
Cuddy, TE | 1 |
Korkushko, OV | 1 |
Sarkisov, KG | 1 |
Butenko, AG | 1 |
Cutler, NR | 1 |
Anders, RJ | 1 |
Jhee, SS | 1 |
Sramek, JJ | 1 |
Awan, NA | 1 |
Bultas, J | 1 |
Woroszylska, M | 1 |
Perez, Y | 1 |
Lellouche, D | 1 |
Nghiem, DK | 1 |
Cachin, JC | 1 |
Castaigne, A | 1 |
Zehender, M | 2 |
Meinertz, T | 2 |
Just, H | 2 |
Volkova, LI | 2 |
Shteĭngart, IuN | 1 |
Doughty, JC | 1 |
Donald, AK | 1 |
Keogh, G | 1 |
Cooke, TG | 1 |
Rumoroso, JR | 1 |
Bodegas, A | 1 |
Subinas, J | 1 |
Montes, PM | 1 |
Sanz, R | 1 |
Rodrigo, D | 1 |
Barrenetxea, JI | 1 |
Golitsyn, SP | 1 |
Malakhov, VI | 1 |
Bakalov, SA | 1 |
Krutanov, IB | 1 |
Maĭkov, EB | 1 |
Bomonina, EV | 1 |
Kul'ginskaia, IV | 1 |
Shabbir, N | 1 |
McAbee, G | 1 |
Fonzari, M | 1 |
Santoloci, D | 1 |
Farinini, D | 1 |
Gardner, MJ | 1 |
Gilbert, M | 1 |
Winterkorn, JM | 1 |
Beckman, RL | 1 |
Hauf-Zachariou, U | 1 |
Blackwood, RA | 1 |
Gunawardena, KA | 1 |
O'Donnell, JG | 1 |
Garnham, S | 1 |
Pfarr, E | 1 |
Swain, RA | 1 |
Kaplan, B | 1 |
Kakhnovskiĭ, IM | 1 |
Sivkov, SI | 1 |
Markova, ZS | 1 |
Ivanova, IL | 1 |
Sivkov, AS | 1 |
Wacke, R | 1 |
Kirchner, A | 1 |
Prall, F | 1 |
Nizze, H | 1 |
Schmidt, W | 1 |
Fischer, U | 1 |
Nitschke, FP | 1 |
Adam, U | 1 |
Fritz, P | 1 |
Belloc, C | 1 |
Drewelow, B | 1 |
Glasser, S | 1 |
Stone, P | 1 |
Deedwania, PC | 1 |
Johnson, M | 1 |
Fakouhi, TD | 1 |
Fetsch, T | 2 |
Burschel, G | 1 |
Breithardt, G | 1 |
Engberding, R | 1 |
Koch, HP | 1 |
Lukl, J | 1 |
Trappe, HJ | 1 |
Treese, N | 1 |
van Poeck, KJ | 1 |
De Simone, A | 1 |
Stabile, G | 1 |
Vitale, DF | 1 |
Turco, P | 1 |
Di Stasio, M | 1 |
Petrazzuoli, F | 1 |
Gasparini, M | 1 |
De Matteis, C | 1 |
Rotunno, R | 1 |
Di Napoli, T | 1 |
Min, JY | 1 |
Sandmann, S | 1 |
Meissner, A | 1 |
Unger, T | 1 |
Simon, R | 1 |
Held, C | 2 |
Eriksson, SV | 2 |
Lee, SH | 1 |
Yu, WC | 1 |
Cheng, JJ | 1 |
Hung, CR | 1 |
Ding, YA | 1 |
Chang, MS | 1 |
Chen, SA | 1 |
Mazzone, C | 1 |
Pandullo, C | 1 |
Scardi, S | 1 |
Salvi, R | 1 |
Miccio, M | 1 |
Cattarini, G | 1 |
Morgera, T | 1 |
Centonze, V | 1 |
Bassi, A | 1 |
Causarano, V | 1 |
Dalfino, L | 1 |
Centonze, A | 1 |
Albano, O | 1 |
Brodin, U | 1 |
Evans, RW | 1 |
Packard, RC | 1 |
Lévy, S | 1 |
Duytschaever, MF | 1 |
Garratt, CJ | 1 |
Allessie, MA | 1 |
Meurling, CJ | 1 |
Ingemansson, MP | 1 |
Roijer, A | 1 |
Carlson, J | 1 |
Lindholm, CJ | 1 |
Smideberg, B | 1 |
Sornmo, L | 1 |
Stridh, M | 1 |
Olsson, SB | 1 |
Pradalier, A | 1 |
Baudesson, G | 1 |
Vincent, D | 1 |
Imberty-Campinos, C | 1 |
Ramanna, H | 1 |
Elvan, A | 1 |
Wittkampf, FH | 1 |
de Bakker, JM | 1 |
Hauer, RN | 1 |
Robles de Medina, EO | 1 |
Busse, D | 1 |
Fromm, MF | 1 |
Mörike, K | 1 |
Drescher, S | 1 |
Kühlkamp, V | 1 |
Eichelbaum, M | 2 |
Tanaka, Y | 1 |
Masuzawa, T | 1 |
Saito, M | 1 |
Yamada, T | 1 |
Shin, DH | 1 |
Kardasis, CT | 1 |
Kim, C | 1 |
Juzych, MS | 1 |
Hughes, BA | 1 |
Keole, NS | 1 |
De Crescenzo, V | 1 |
Dubuis, E | 1 |
Constantin, S | 1 |
Rebocho, M | 1 |
Girardin, C | 1 |
Bonnet, P | 1 |
Vandier, C | 1 |
Kentera, D | 1 |
Susić, D | 1 |
Zdravković, M | 1 |
Figueira, RH | 2 |
Bozza, AE | 2 |
Guimarães, F | 2 |
Terra, LS | 1 |
Silva, O | 1 |
Pereira, E | 1 |
Maiolino, E | 1 |
Dohmann, HJ | 2 |
Meneghelo, RS | 1 |
Duprat, R | 1 |
Batlouni, M | 1 |
Severino, CA | 1 |
Armaganijan, D | 1 |
Magalhães, HM | 1 |
Feher, J | 1 |
Oliveira, JM | 1 |
Wagner, M | 1 |
Khalsa, A | 1 |
Olsson, B | 1 |
Henriksson, BA | 1 |
De'Thomatis, M | 1 |
Falciola, N | 1 |
Gallesio, R | 1 |
Vichi, FL | 1 |
Nobre, F | 1 |
Evora, P | 1 |
Ribeiro, PJ | 1 |
Papa, MV | 1 |
Pauzner, H | 1 |
David, D | 1 |
Padilha, JC | 1 |
Tasca, R | 1 |
de Patta, M | 1 |
Weiskopf, JS | 1 |
Scherr, C | 1 |
de Mendonça, JV | 1 |
Spear, JF | 1 |
Horowitz, LN | 1 |
Hodess, AB | 1 |
MacVaugh, H | 1 |
Moore, EN | 1 |
Sapire, DW | 1 |
Mongkolsmai, C | 1 |
O'Riordan, AC | 1 |
Pasini, U | 1 |
Carvalho, ET | 1 |
Reis, VG | 1 |
Papaléo Netto, M | 1 |
Lundström, T | 1 |
Moor, E | 1 |
Rydén, L | 1 |
Chou, SY | 1 |
Reiser, I | 1 |
Porush, JG | 1 |
Tehindrazanarivelo, AD | 1 |
Visy, JM | 1 |
Bousser, MG | 1 |
Dobrotvorskaia, TE | 1 |
Kazakevich, EV | 1 |
Kuznetsova, LA | 1 |
Kotlov, AP | 1 |
Kubac, G | 1 |
Malowany, L | 1 |
Hohnloser, S | 1 |
Müller, B | 1 |
Gibbs, JS | 1 |
McAlpine, HM | 1 |
Wright, C | 1 |
McLenachan, JM | 1 |
Sparrow, J | 1 |
Sutton, G | 1 |
Dargie, HJ | 2 |
Fox, KM | 1 |
Matsuda, M | 1 |
Matsuda, Y | 1 |
Yamagishi, T | 1 |
Takahashi, T | 1 |
Haraguchi, M | 1 |
Tada, T | 1 |
Kusukawa, R | 1 |
Podszus, Th | 1 |
Peter, JH | 1 |
Völger, KD | 1 |
Zilles, P | 1 |
Borsari, G | 1 |
Markley, HG | 1 |
Saakian, AG | 1 |
Bussone, G | 1 |
Leone, M | 1 |
Peccarisi, C | 1 |
Micieli, G | 1 |
Granella, F | 1 |
Magri, M | 1 |
Manzoni, GC | 1 |
Nappi, G | 1 |
Chizh, VD | 1 |
Lewis, RV | 2 |
McMurray, J | 1 |
McDevitt, DG | 3 |
Tanowitz, HB | 1 |
Morris, SA | 1 |
Weiss, LM | 1 |
Bilezikian, JP | 1 |
Factor, SM | 1 |
Wittner, M | 1 |
Pawlicki, L | 1 |
Tchórzewski, H | 1 |
Trznadel, K | 1 |
Luciak, M | 1 |
Kantorski, J | 1 |
Pokoca, L | 1 |
Orynchak, Ma | 1 |
Leon, MB | 1 |
Rosing, DR | 1 |
Bonow, RO | 1 |
Epstein, SE | 1 |
Kostuk, WJ | 1 |
Pflugfelder, P | 1 |
Lohmeier, TE | 1 |
Montani, JP | 1 |
Smith, MJ | 1 |
Rushing, EL | 1 |
Channer, KS | 2 |
James, M | 1 |
Eiskjaer, H | 1 |
Pedersen, EB | 1 |
Rasmussen, LM | 1 |
Jespersen, B | 1 |
Belli, B | 1 |
Michelucci, A | 1 |
Monizzi, D | 1 |
Barletta, G | 1 |
Morace, G | 2 |
Padeletti, L | 1 |
Román, O | 1 |
Gac, JC | 1 |
Ramírez, J | 1 |
Rebolledo, H | 1 |
Valenzuela, MA | 1 |
Antunez, C | 1 |
Irvine, N | 1 |
Mavrov, II | 1 |
Goncharenko, MS | 1 |
Kondakova, AK | 1 |
Petruniaka, VV | 1 |
Pomfret, SM | 1 |
Beasley, CR | 1 |
Challenor, V | 1 |
Holgate, ST | 1 |
Furkalo, NK | 1 |
Zaĭtseva, VI | 1 |
Mølgaard, H | 1 |
Bjerregaard, P | 1 |
Jørgensen, HS | 1 |
Klitgaard, NA | 1 |
Maul, FD | 1 |
Hopf, R | 1 |
Hör, G | 1 |
Standke, R | 1 |
Richter, H | 1 |
Olbrich, HG | 1 |
Happ, J | 1 |
Kimmel, B | 1 |
Goldberger, J | 1 |
Phillippides, G | 1 |
Klein, N | 1 |
Grebb, JA | 1 |
Shelton, RC | 1 |
Taylor, EH | 1 |
Bigelow, LB | 1 |
Miura, D | 1 |
Somberg, JC | 1 |
Kendall, MJ | 1 |
Horton, RC | 1 |
Smith, SR | 1 |
Weiner, DA | 1 |
Klein, MD | 1 |
Cutler, SS | 1 |
Papouchado, M | 1 |
James, MA | 1 |
Pitcher, DW | 1 |
Rees, JR | 1 |
Lewis, R | 1 |
Lakhani, M | 1 |
Moreland, TA | 1 |
Findlay, IN | 1 |
MacLeod, K | 1 |
Gillen, G | 1 |
Elliott, AT | 1 |
Aitchison, T | 1 |
Tourjman, SV | 2 |
Bloom, DM | 2 |
Nair, NP | 2 |
Merzon, KA | 1 |
Doviner, AD | 1 |
Zolotov, NA | 1 |
Kolomiets, VV | 1 |
Kiriaev, AA | 1 |
Manoharan, S | 1 |
Kaul, UA | 1 |
Khalilullah, M | 1 |
Ochs, HR | 1 |
Anda, L | 1 |
Greenblatt, DJ | 1 |
Ocken, S | 1 |
Spivack, C | 1 |
Kaski, JC | 1 |
Plaza, LR | 1 |
Meran, DO | 1 |
Araujo, L | 1 |
Chierchia, S | 1 |
Maseri, A | 1 |
Dimitrov, D | 1 |
Arsov, D | 1 |
Serafimova, E | 1 |
von Bernuth, G | 1 |
Lang, D | 1 |
Belz, GG | 1 |
Shkhvatsabaia, IK | 1 |
Miasnikov, LA | 1 |
Grigor'iants, RA | 1 |
Dubinina, LT | 1 |
Nissen, P | 1 |
Alexander, K | 1 |
Nedden, KH | 1 |
Fabel, H | 1 |
Maranhão, MF | 1 |
Germiniani, H | 1 |
Rojas, RR | 1 |
Lacerda, FS | 1 |
De Oliveira, PF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
Intervention | Participants (Count of Participants) |
---|---|
Phase Ib | 0 |
14 reviews available for verapamil and Chronic Disease
Article | Year |
---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Point of View: Electrophysiological Endpoints Differ When Comparing the Mode of Action of Highly Successful Anti-arrhythmic Drugs in the CAVB Dog Model With TdP.
Topics: Action Potentials; Aniline Compounds; Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Chron | 2019 |
[Acute and chronic headaches].
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
[The efficacy of verapamil in sustained monomorphic ventricular tachycardia].
Topics: Adult; Cardiac Pacing, Artificial; Chronic Disease; Drug Evaluation; Electrocardiography, Ambulatory | 1994 |
[Control of heart rate and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides; Diltiazem; | 1996 |
Diagnosis, prophylaxis, and treatment of headaches in the athlete.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; | 1997 |
Pharmacologic management of atrial fibrillation: current therapeutic strategies.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; | 2001 |
[Treatment of cluster headache].
Topics: Anti-Inflammatory Agents; Calcium Channel Blockers; Chronic Disease; Cluster Headache; Combined Moda | 2001 |
[Medical therapy of chronic coronary insufficiency].
Topics: Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Digitalis Glycosides; Humans; Lidofl | 1978 |
Verapamil and migraine prophylaxis: mechanisms and efficacy.
Topics: Animals; Chronic Disease; Clinical Trials as Topic; Cluster Headache; Humans; Migraine Disorders; Re | 1991 |
Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Cl | 1985 |
Supraventricular tachyarrhythmias: their evaluation and therapy.
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blockers | 1986 |
Calcium antagonists and chronic cardiac failure.
Topics: Calcium Channel Blockers; Chronic Disease; Diltiazem; Heart Failure; Humans; Nifedipine; Verapamil | 1986 |
Calcium-channel blockers and systemic hypertension.
Topics: Acute Disease; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Diltiazem; Drug | 1985 |
57 trials available for verapamil and Chronic Disease
Article | Year |
---|---|
Phase I safety and tolerability study of topical verapamil HCl in chronic rhinosinusitis with nasal polyps.
Topics: Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis; Verapamil | 2022 |
Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Coron | 2009 |
Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.
Topics: 4-Aminobenzoic Acid; Adult; Aged; Anthocyanins; Antioxidants; Biological Therapy; Chronic Disease; D | 2013 |
Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Diagnosis, Computer-Assiste | 1980 |
Verapamil in the management of chronic hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Chronic Disease; Clinical Trials as Top | 1980 |
Verapamil in treatment of chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as To | 1983 |
Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female | 1983 |
Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Clinical Tr | 1983 |
[Changes in the physical load tolerance of stenocardia patients taking obzidan, korinfar and izoptin separately and together].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Drug Th | 1984 |
Combined therapy with Ca-antagonists and beta-adrenergic receptor blocking agents in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Drug Therapy, Combination; | 1984 |
Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Drug Administration Schedule; El | 1984 |
[Comparative study of verapamil and fendiline in the treatment of chronic coronary insufficiency. Clinical and ergometric evaluation].
Topics: Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electrocardiograph | 1982 |
Calcium antagonist drugs in chronic stable angina. Comparison of verapamil and nifedipine.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double-Blin | 1981 |
Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Blood Pressure; Chronic Disease; Double-Blin | 1982 |
Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Electrocardiography; Exercise Te | 1982 |
Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Chronic Disease; Constipation; Delayed-Action Pr | 1995 |
[Amiodarone and verapamil/quinidine in treatment of patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Drug; Drug Admin | 1994 |
[The use of verapamil in the treatment of hemicrania without aura].
Topics: Adolescent; Adult; Chronic Disease; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Middl | 1994 |
Carvedilol versus verapamil in chronic stable angina: a multicentre trial.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Carbaz | 1997 |
[The possibilities of isoptin treatment of pulmonary hypertension in patients with chronic obstructive bronchitis].
Topics: Adult; Aged; Bronchitis; Calcium Channel Blockers; Chronic Disease; Female; Humans; Hypertension, Pu | 1997 |
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; Calcium | 1999 |
[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Dis | 1999 |
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Elect | 1999 |
Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Elect | 1999 |
Left atrial and appendage mechanical function after pharmacological or electrical cardioversion in patients with chronic atrial fibrillation: a multicenter, randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial Function, Left; Blood Fl | 2000 |
Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Exerc | 2000 |
Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.
Topics: Administration, Oral; Aged; Area Under Curve; Atrial Fibrillation; Blood Pressure; Calcium Channel B | 2001 |
Topical verapamil in glaucoma filtration surgery.
Topics: Administration, Topical; Aged; Calcium Channel Blockers; Chemotherapy, Adjuvant; Chronic Disease; Do | 2001 |
[Cycloergometric evaluation of the continuous use of verapamil 360 mg/per day in chronic coronary insufficiency].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Drug | 1977 |
[Cycloergometric evaluation of the effects of verapamil in chronic coronary insufficiency].
Topics: Administration, Oral; Adult; Aged; Body Weight; Chronic Disease; Clinical Trials as Topic; Coronary | 1977 |
[Effects of verapamil on the cycloergometric test in patients of coronary artery disease].
Topics: Administration, Oral; Adult; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Drug Evalu | 1977 |
[Initial experience. Comparative study of verapamil and nifedipine in the treatment of coronary insufficiency. Evaluation by a cycloergometric test].
Topics: Adult; Aged; Chronic Disease; Cineangiography; Clinical Trials as Topic; Coronary Disease; Double-Bl | 1978 |
Effect of oral verapamil on ventricular irregularity in long-standing atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Blood Pressure; Chronic Disease; Clinical Tr | 1979 |
[Use of verapamil in the treatment of ventricular extrasystole in chronic Chagas' heart disease].
Topics: Cardiomyopathies; Chagas Disease; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Drug | 1977 |
[Value of verapamil by oral administration in the treatment of chronic heart dysrhythmias].
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Human | 1976 |
Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Electroca | 1992 |
Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Protocols; Electric Countershock; Exercise Test | 1992 |
Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Electrocardiography; Fe | 1992 |
Double-blind randomised placebo-controlled dose-efficacy study of sustained release verapamil in chronic stable angina.
Topics: Aged; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Dru | 1991 |
[The therapeutic effects of the calcium blocker verapamil in chronic diarrhea. Preliminary communication].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Colitis; Diarrhea; Diverticulum, Colon; Dose-Respon | 1991 |
Double blind comparison of lithium and verapamil in cluster headache prophylaxis.
Topics: Adult; Chronic Disease; Cluster Headache; Double-Blind Method; Female; Humans; Lithium; Male; Middle | 1990 |
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atenolol; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides | 1989 |
Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Cl | 1985 |
Comparative effects of calcium entry-blocking drugs, beta-blocking drugs, and their combination in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease | 1987 |
[Comparative study of the effect of 3 calcium antagonists in chronic stable angina].
Topics: Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical Trials as | 1988 |
Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Diltiazem; Female; Humans; | 1987 |
Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.
Topics: Aged; Atrial Fibrillation; Cardiac Output; Chronic Disease; Digoxin; Diltiazem; Heart Rate; Humans; | 1988 |
Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Digoxin; Double-Blind Method; | 1988 |
Calcium-channel blockers for combined angina pectoris and systemic hypertension.
Topics: Adult; Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chr | 1986 |
A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1986 |
Efficacy of sustained-release verapamil in chronic stable angina pectoris.
Topics: Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparati | 1987 |
Calcium-channel blockers for combined systemic hypertension and myocardial ischemia.
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Coronary Disea | 1987 |
Towards improved control of atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Circadian Rhythm; Clinical Trials as Topic; Digoxin; Dos | 1987 |
A comparison of verapamil and digoxin in the treatment of atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Digoxin; Dose-Response Relatio | 1987 |
A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double-B | 1987 |
Diltiazem, verapamil, and quinidine in patients with chronic atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Benzazepines; Chronic Disease; Clinical Trials as Topic | 1985 |
[Isoptin treatment of patients with various forms of chronic coronary insufficiency].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinica | 1970 |
77 other studies available for verapamil and Chronic Disease
Article | Year |
---|---|
P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2021 |
Physiology and analysis of the electrocardiographic T wave in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal | 2013 |
Verapamil modulates interleukin-5 and interleukin-6 secretion in organotypic human sinonasal polyp explants.
Topics: Calcium Channel Blockers; Cells, Cultured; Chronic Disease; Dexamethasone; Enterotoxins; Humans; Imm | 2015 |
Stimulation of Cardiomyocyte Regeneratory Reactions under Conditions of Cytopathic Hypercholesterolemia.
Topics: Animals; Cell Proliferation; Chronic Disease; Hypercholesterolemia; Male; Myocardium; Myocytes, Card | 2015 |
Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps.
Topics: Case-Control Studies; Chronic Disease; Humans; Immunologic Factors; Nasal Polyps; Rhinitis; Sinusiti | 2017 |
L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure.
Topics: Acute Disease; Animals; Anticonvulsants; Benzamides; Benzoxazines; Calcium Channels, L-Type; Cannabi | 2012 |
[Effect of long term administration of finoptin on the morphofunctional state of working cells of the intact myocardium in modeling of chronic coronary insufficiency].
Topics: Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Drug Evaluation | 2002 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
[Prophylactic treatment of cluster headache with verapamil].
Topics: Adolescent; Adult; Chronic Disease; Cluster Headache; Female; Humans; Male; Middle Aged; Retrospecti | 2003 |
Outpatient intravenous dihydroergotamine for refractory cluster headache.
Topics: Adult; Aged; Ambulatory Care; Analgesics, Non-Narcotic; Chronic Disease; Cluster Headache; Dihydroer | 2004 |
Verapamil and lymphomatoid papulosis in chronic cluster headache.
Topics: Aged; Chronic Disease; Cluster Headache; Humans; Lymphomatoid Papulosis; Male; Verapamil | 2004 |
[Dose-effect dependence after taking calcium antagonists in exertion stenocardia patients].
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Drug E | 1983 |
Efficacy of verapamil in chronic, recurrent ventricular tachycardia.
Topics: Adult; Age Factors; Chronic Disease; Drug Evaluation; Electrocardiography; Female; Heart Ventricles; | 1983 |
[Therapeutic association in chronic stable angina: verapamil plus beta-blockers].
Topics: Angina Pectoris; Chronic Disease; Drug Therapy, Combination; Humans; Sympatholytics; Verapamil | 1983 |
The influence of verapamil on serum digoxin concentration.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Drug I | 1982 |
Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Blood Pressure; Chronic Disease; Digoxin; Dose-Response R | 1982 |
Effects of verapamil on exercise performance in chronic angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Chronic Disease; Humans; Middle Aged; Physical Exertion; Vera | 1982 |
[Verapamil (an antagonist of calcium) and its effect on chronic pulmonary hypertension in humans].
Topics: Blood Pressure; Calcium Channel Blockers; Chronic Disease; Humans; Hypertension, Pulmonary; Verapami | 1982 |
Calcium channel blockers in chronic stable angina. A review.
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Diltiazem; Electrocardiography; Humans; | 1982 |
Verapamil disposition kinetics in chronic atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Chronic Disease; Female; Humans; Infusions, Parente | 1981 |
Treatment of chronic pulmonary disease.
Topics: Chronic Disease; Electroshock; Humans; Lung Diseases; Tachycardia; Verapamil | 1980 |
Verapamil and supraventricular tachyarrhythmias: beneficial effect in patients with chronic pulmonary disease.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Blood Gas Analysis; Chronic Disease; Electrocardiography; | 1980 |
[Anti-arrhythmic effectiveness of isoptin in ischemic heart disease in the middle-aged and elderly].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Coronary Disease; Drug Evaluati | 1980 |
Chronic irregular idiopathic ventricular tachycardia with myocardial dysfunction suppressed by verapamil in an adult.
Topics: Adult; Cardiac Pacing, Artificial; Chronic Disease; Echocardiography; Electrocardiography; Electroca | 1994 |
[Individual approach to vasodilator treatment of pulmonary hypertension in chronic bronchitis].
Topics: Adult; Aminophylline; Bronchitis; Chronic Disease; Humans; Hydralazine; Hypertension, Pulmonary; Mid | 1994 |
Stercoral perforation with verapamil.
Topics: Aged; Chronic Disease; Constipation; Female; Humans; Hypothyroidism; Intestinal Perforation; Sigmoid | 1994 |
[Permanent repetitive nonparoxysmal ventricular tachycardia. I. The electrocardiographic manifestations and possible mechanisms of its occurrence].
Topics: Adolescent; Adult; Cardiac Pacing, Artificial; Chronic Disease; Electrocardiography; Electrocardiogr | 1994 |
Adolescent chronic paroxysmal hemicrania responsive to verapamil monotherapy.
Topics: Adolescent; Chronic Disease; Cluster Headache; Female; Humans; Treatment Outcome; Verapamil | 1994 |
Recovery from ocular ischemic syndrome after treatment with verapamil.
Topics: Aged; Aged, 80 and over; Blindness; Calcium Channel Blockers; Chronic Disease; Eye; Glaucoma, Open-A | 1995 |
Up-regulation of cytochrome P450 1A2, 2C9, and 2E1 in chronic pancreatitis.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Chronic Disease; Cytochrome P-450 CYP1A2; Cytochrome P-4 | 1998 |
[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology].
Topics: Adult; Aged; Chronic Disease; Contraindications; Drug Interactions; Female; Guidelines as Topic; Hea | 1999 |
Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Topics: Adrenergic beta-Agonists; Aequorin; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic | 1999 |
Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling.
Topics: Adaptation, Physiological; Animals; Atrial Function; Calcium Channel Blockers; Cardiac Pacing, Artif | 2000 |
Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cluster Headache; Humans; Indometha | 2000 |
Fifteen-minute, bilateral, posttraumatic headaches.
Topics: Adult; Chronic Disease; Craniocerebral Trauma; Headache; Humans; Male; Recurrence; Time Factors; Ver | 2000 |
Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chr | 2000 |
Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Chronic Disease; Female; Heart Co | 1999 |
Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Electrocardiography; Female; Heart Atria; Humans; Infusi | 2001 |
Inhibitory effects of verapamil and nitroglycerin on contraction and cytosolic Ca2+ levels in cerebrovascular smooth muscle during chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Chronic Disease; Cytosol; Disease Models, Anima | 2001 |
Halothane differentially decreases 5-hydroxytryptamine-induced contractions in normal and chronic hypoxic rat pulmonary arteries.
Topics: Anesthetics, Inhalation; Animals; Cadmium; Calcium Channel Blockers; Chronic Disease; Halothane; Hyp | 2001 |
[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Ch | 2001 |
Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: Animals; Aspirin; Biological Transport; Calcium; Cardiomegaly; Chronic Disease; Female; Haplorhini; | 1979 |
The beneficial effects of verapamil in chronic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Female; Heart Rate; Humans; Male; Middle Aged; | 1979 |
Drug treatment of chronic stable angina pectoris.
Topics: Angina Pectoris; Chronic Disease; Humans; Nifedipine; Nitrites; Perhexiline; Verapamil | 1978 |
[Comparative study of the medium term use of verapamil and perhexiline in the treatment of chronic coronary insufficiency. Clinical and cycloergometric evaluation].
Topics: Adult; Aged; Chronic Disease; Coronary Disease; Electrocardiography; Exercise Test; Female; Humans; | 1978 |
[Verapamil associated with quinidine in the treatment of chronic atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; | 1978 |
Cellular electrophysiology of human myocardial infarction. 1. Abnormalities of cellular activation.
Topics: Action Potentials; Adult; Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Chronic Disease; H | 1979 |
Control of chronic ectopic supraventricular tachycardia with verapamil.
Topics: Child, Preschool; Chronic Disease; Female; Humans; Tachycardia; Verapamil | 1979 |
Reversal of Na+ retention in chronic caval dogs by verapamil: contribution of medullary circulation.
Topics: Animals; Cardiac Output, Low; Chronic Disease; Constriction, Pathologic; Dinoprostone; Dogs; Female; | 1992 |
Ipsilateral cluster headache and chronic paroxysmal hemicrania: two case reports.
Topics: Adult; Chronic Disease; Cluster Headache; Drug Therapy, Combination; Humans; Indomethacin; Male; Mid | 1992 |
[The chronotropic and hemodynamic effects of finoptin in patients with a permanent form of atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Chronic Disease; Digoxin; Drug Evaluation; Drug | 1992 |
Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Chronic Disease; Digoxin; Exercise; Heart Rate; Humans; Male; Middle Aged | 1991 |
[Combination therapy in chronic heart failure. Hemodynamic effects with a calcium antagonist-diuretic combination].
Topics: Adult; Aged; Chronic Disease; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hydrochlorothi | 1991 |
[The effect of calcium antagonists on the rate of gastric emptying in patients with duodenal peptic ulcer and the dumping syndrome].
Topics: Adult; Calcium Channel Blockers; Chronic Disease; Dumping Syndrome; Duodenal Ulcer; Female; Gastric | 1990 |
[The use of propranolol and verapamil in patients with ischemic heart disease].
Topics: Adult; Arrhythmias, Cardiac; Chronic Disease; Coronary Disease; Drug Evaluation; Female; Heart Failu | 1990 |
Effect of verapamil on the development of chronic experimental Chagas' disease.
Topics: Adenylyl Cyclases; Animals; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; Disease Models, | 1989 |
[The effect of calcium antagonists on pulmonary hemodynamics in patients with chronic bronchitis with manifest and latent pulmonary hypertension].
Topics: Adult; Bronchitis; Calcium Channel Blockers; Chronic Disease; Drug Evaluation; Female; Hemodynamics; | 1989 |
Effect of verapamil on chemiluminescence of peripheral blood neutrophils during hemodialysis in chronic uremic patients.
Topics: Adult; Cell Count; Cell Division; Chronic Disease; Female; Free Radicals; Humans; Kidney Failure, Ch | 1989 |
[Effect of digoxin, furosemide and finoptin on the central hemodynamics in hypertension].
Topics: Aged; Chronic Disease; Digoxin; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Hear | 1989 |
Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Chronic Disease; Dogs | 1989 |
Pindolol, not verapamil, in combination with digoxin is the treatment of choice in chronic atrial fibrillation.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Drug Therapy, Combination; Humans; Pindolol; Verapami | 1989 |
Sustained release verapamil in renal hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; | 1988 |
Reversible cardiomyopathy following chronic supraventricular tachycardia.
Topics: Adult; Cardiomyopathy, Dilated; Chronic Disease; Digoxin; Drug Combinations; Electrocardiography; Hu | 1988 |
[Finoptin treatment of patients with psoriasis].
Topics: Adolescent; Adult; Aged; Calcium; Chronic Disease; Drug Evaluation; Humans; Middle Aged; Psoriasis; | 1988 |
[Combined obzidan and verapamil treatment of ischemic heart disease patients].
Topics: Chronic Disease; Coronary Disease; Drug Evaluation; Drug Therapy, Combination; Exercise Test; Hemody | 1987 |
24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Delayed-Action Preparations; Drug Administration | 1987 |
Radionuclide ventriculography: acute and chronic response to verapamil in patients with hypertrophic cardiomyopathy.
Topics: Acute Disease; Adolescent; Adult; Aged; Cardiomyopathy, Hypertrophic; Chronic Disease; Diastole; Fem | 1987 |
Verapamil in the treatment of chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Schizophrenia; Verapamil | 1987 |
Verapamil in refractory schizophrenia: a case report.
Topics: Adult; Chronic Disease; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Male; Schiz | 1987 |
[Hemodynamic effect of verapamil and nifedipine in chronic heart failure].
Topics: Calcium; Chronic Disease; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Nifedi | 1986 |
Effectiveness of oral verapamil in controlling ventricular rate in patients with chronic atrial fibrillation receiving digoxin.
Topics: Adolescent; Adult; Atrial Fibrillation; Chronic Disease; Digoxin; Drug Therapy, Combination; Female; | 1986 |
Improved coronary supply: prevailing mechanism of action of nitrates in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Cardiac Volume; Chronic Disease; Coronary | 1985 |
[Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide].
Topics: Adult; Blood Pressure; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; | 1985 |
[Verapamil for regulation of cardiac rhythm disorders. Experience with our own patients].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Circulation; Cardiac Complexes, Pre | 1970 |
[Repetitive paroxysmal tachycardia in childhood (author's transl)].
Topics: Adolescent; Child, Preschool; Chronic Disease; Digitalis Glycosides; Electrocardiography; Female; He | 1974 |
[Drug therapy of chronic arterial occlusion of the extremities by intraarterial administration of Verapramil].
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Electrocardiography; Femoral Artery; Heart Rate; Human | 1972 |
[Use of verapamil in the treatment of cardiac arrhythmias].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Child, Pr | 1971 |